September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Exacerbation of Macular Edema Associated with Hyperbaric Oxygen Therapy
Author Affiliations & Notes
  • Stephen M. Hypes
    Neurology & Ophthalmology, Michigan State University COM, Dearborn, Michigan, United States
    Ophthalmology, Beaumont Health - Southshore Campus, Trenton, Michigan, United States
  • Ashkan Abbey
    Associated Retina Consultants, Royal Oak, Michigan, United States
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan, United States
  • Yoshihiro Yonekawa
    Associated Retina Consultants, Royal Oak, Michigan, United States
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan, United States
  • Jeremy D Wolfe
    Associated Retina Consultants, Royal Oak, Michigan, United States
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan, United States
  • Footnotes
    Commercial Relationships   Stephen Hypes, None; Ashkan Abbey, None; Yoshihiro Yonekawa, None; Jeremy Wolfe, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2678. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephen M. Hypes, Ashkan Abbey, Yoshihiro Yonekawa, Jeremy D Wolfe; Exacerbation of Macular Edema Associated with Hyperbaric Oxygen Therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2678.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Hyperbaric oxygen therapy (HBOT) is being marketed as a treatment for retinovascular diseases without scientific evidence. HBOT has been shown to increase VEGF levels in tissues; therefore, we hypothesize HBOT may in fact worsen the vascular permeability of diseased retinal vasculature. We report a patient who developed an abnormally acute and diffuse macular edema from a preexisting retinal arterial macroaneurysm (RAM) following HBOT.

Methods : Retrospective clinical analysis of visual acuity (VA), spectral domain optical coherence tomography (SD-OCT), and fluorescein angiography (FA) before and after administration of HBOT in a 71-year-old woman with a preexisting RAM.

Results : The patient presented with acute onset of blurry vision OS. BCVA was 20/200, and examination revealed submacular hemorrhage OS and a new RAM as seen on FA. The patient underwent vitrectomy with subretinal tissue plasminogen activator and pneumatic displacement. VA improved to 20/150 one week after surgery. One week post-operative SD-OCT showed trace residual subretinal fluid, and no intraretinal edema. In the following weeks, the patient underwent 7 consecutive sessions of HBOT. At post-operative week 5, VA OS had decreased to 20/200 and a new, acute, diffuse, and severe macular edema was noted. Fluorescein angiography demonstrated increased leakage from the RAM and surrounding angiopathic vessels. The patient was directed to discontinue HBOT, and the edema quickly resolved with intravitreal ranibizumab treatment.

Conclusions : HBOT may exacerbate macular edema from retinovascular diseases. We recommend that retinovascular disease not be listed as an indication, but as a relative contraindication for HBOT, until proven otherwise.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×